Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
暂无分享,去创建一个
S. von Felten | O. Sartor | R. de Wit | J. D. de Bono | A. Meisel | D. Vogt | H. Liewen | F. Stenner-Liewen